Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Classical hematology 1

Conditions

Venous Thrombosis 1Venous Thromboembolism 1Thromboembolism 1Pulmonary Embolism 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × isoquercitrin × 1 year × Clear all
NCT07303894 2026-04-16

A Study of Isoquercetin in People With Ovarian Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
90 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT06861088 2026-02-02

CATIQ P3

Quercis Pharma AG

Phase 3 Recruiting
480 enrolled
Classical hematologyGastrointestinal

Pancreatic Neoplasms, Pulmonary Embolism, Thromboembolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡